Literature DB >> 24648994

The fibroblast growth factor receptor 2-mediated extracellular signal-regulated kinase 1/2 signaling pathway plays is important in regulating excision repair cross-complementary gene 1 expression in hepatocellular carcinoma.

Gang Chen1, Hong Qiu2, Shandong Ke1, Shaoming Hu1, Shiying Yu2, Shengquan Zou3.   

Abstract

Excision repair cross-complementary gene 1 (ERCC1) is a downstream regulatory target of fibroblast growth factor receptor 2 (FGFR2); however, the mechanism of its action has not been elucidated. The cascades downstream of FGFR2 include the PKC, Ras/Raf/MEK/ERK, JAK/STAT and PI3K pathways. ERCC1 is considered to be a closely related downstream target gene of extracellular signal-regulated kinase (ERK)1/2, since ERCC1 mRNA and protein levels may be inhibited by the ERK inhibitor U0126. It was hypothesized that FGFR2, which specifically binds with fibroblast growth factor 7 (FGF7), may regulate ERCC1 gene expression through the ERK signaling pathway. The aim of the present study was to explore the association between the regulatory effect of FGFR2 on ERCC1 gene expression and the p-ERK1/2 signaling pathway in a drug-resistant hepatocellular carcinoma (HCC) cell line. The drug-resistant cell line HepG2/OXA and its parental cell line HepG2 were transfected with Bek shRNA in the logarithmic growth phase. Transfected and untransfected HepG2 and HepG2/OXA cells were then stimulated with FGF7 and changes in the protein expression of FGFR2, p-ERK1/2 and ERCC1 was detected with western blot analysis. Following transfection, HepG2/T and HepG2/OXA/T cells were observed to grow stably in a screening medium containing puromycin. The western blot analysis demonstrated a significant decrease in the protein expressions of FGFR2, p-ERK1/2 and ERCC1 in HepG2/T and HepG2/OXA/T cells as compared to untransfected cells. Expression of FGFR2, p-ERK1/2 and ERCC1 in HepG2/OXA cells was significantly increased compared to the parental HepG2 cells. Following stimulation with FGF7, the expression of FGFR2, p-ERK1/2 and ERCC1 was increased, with significant differences between HepG2 and HepG2/OXA cells in the expression of p-ERK1/2 and ERCC1. No differences were detected in the protein levels following Bek shRNA transfection in HepG2/T and HepG2/OXA/T cells. In conclusion, the FGFR2-mediated ERK1/2 signaling pathway in HCC cells plays an important role in the regulation of ERCC1 expression.

Entities:  

Keywords:  excision repair cross-complementary gene 1; extracellular signal-regulated kinase; fibroblast growth factor receptor 2; hepatocellular carcinoma

Year:  2013        PMID: 24648994      PMCID: PMC3917011          DOI: 10.3892/br.2013.96

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  18 in total

1.  Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma.

Authors:  Shigeru Ueda; Ken Shirabe; Kazutoyo Morita; Kenji Umeda; Hiroto Kayashima; Hideaki Uchiyama; Yuji Soejima; Akinobu Taketomi; Yoshihiko Maehara
Journal:  Ann Surg Oncol       Date:  2010-11-13       Impact factor: 5.344

2.  A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.

Authors:  Hong Qiu; Masakazu Yashiro; Xiaotian Zhang; Atsushi Miwa; Kosei Hirakawa
Journal:  Cancer Lett       Date:  2011-04-08       Impact factor: 8.679

Review 3.  FGF signaling network in the gastrointestinal tract (review).

Authors:  Masuko Katoh; Masaru Katoh
Journal:  Int J Oncol       Date:  2006-07       Impact factor: 5.650

4.  Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma.

Authors:  Alain Fautrel; Lise Andrieux; Orlando Musso; Karim Boudjema; André Guillouzo; Sophie Langouët
Journal:  J Hepatol       Date:  2005-04-25       Impact factor: 25.083

5.  Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis.

Authors:  Christine Gauglhofer; Sandra Sagmeister; Waltraud Schrottmaier; Carina Fischer; Chantal Rodgarkia-Dara; Thomas Mohr; Stefan Stättner; Christoph Bichler; Daniela Kandioler; Fritz Wrba; Rolf Schulte-Hermann; Klaus Holzmann; Michael Grusch; Brigitte Marian; Walter Berger; Bettina Grasl-Kraupp
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

6.  Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.

Authors:  Jen-Chung Ko; Min-Shao Tsai; Ya-Hsun Kuo; Yu-Fan Chiu; Shao-Hsing Weng; Ying-Chen Su; Yun-Wei Lin
Journal:  Biochem Pharmacol       Date:  2010-12-17       Impact factor: 5.858

7.  GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling.

Authors:  Ailin Bai; Kristan Meetze; Nhi Y Vo; Sriram Kollipara; Elizabeth K Mazsa; William M Winston; Solly Weiler; Laura L Poling; Ting Chen; Nesreen S Ismail; Jinwei Jiang; Lorena Lerner; Jeno Gyuris; Zhigang Weng
Journal:  Cancer Res       Date:  2010-08-13       Impact factor: 12.701

8.  Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.

Authors:  Cha-Kyung Youn; Mi-Hwa Kim; Hyun-Ju Cho; Hong-Beum Kim; In-Youb Chang; Myung-Hee Chung; Ho Jin You
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

Review 9.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

Review 10.  Diagnosis and treatment of hepatocellular carcinoma.

Authors:  Hashem B El-Serag; Jorge A Marrero; Lenhard Rudolph; K Rajender Reddy
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

View more
  5 in total

1.  Expression of aquaporin 8 and phosphorylation of Erk1/2 in cervical epithelial carcinogenesis: correlation with clinicopathological parameters.

Authors:  Heng Chang; Yonghua Shi; Talaf Tuokan; Rui Chen; Xiaoqian Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  The effect of hydroxy safflower yellow A on coronary heart disease through Bcl-2/Bax and PPAR-γ.

Authors:  Dayan Zhou; Zongjie Qu; Hao Wang; Yong Su; Yazhu Wang; Weiwei Zhang; Zhe Wang; Qiang Xu
Journal:  Exp Ther Med       Date:  2017-11-01       Impact factor: 2.447

3.  TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p.

Authors:  Jonathan Berrout; Eleni Kyriakopoulou; Lavanya Moparthi; Alexandra S Hogea; Liza Berrout; Cristina Ivan; Mihaela Lorger; John Boyle; Chris Peers; Stephen Muench; Jacobo Elies Gomez; Xin Hu; Carolyn Hurst; Thomas Hall; Sujanitha Umamaheswaran; Laura Wesley; Mihai Gagea; Michael Shires; Iain Manfield; Margaret A Knowles; Simon Davies; Klaus Suhling; Yurema Teijeiro Gonzalez; Neil Carragher; Kenneth Macleod; N Joan Abbott; George A Calin; Nikita Gamper; Peter M Zygmunt; Zahra Timsah
Journal:  Nat Commun       Date:  2017-10-16       Impact factor: 14.919

Review 4.  Advances of Fibroblast Growth Factor/Receptor Signaling Pathway in Hepatocellular Carcinoma and its Pharmacotherapeutic Targets.

Authors:  Haijun Wang; Jie Yang; Ke Zhang; Jia Liu; Yushan Li; Wei Su; Na Song
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

5.  Construction and analysis for differentially expressed long non-coding RNAs and mRNAs in acute myocardial infarction.

Authors:  Ning Song; Xiang-Mei Li; Jun-Yi Luo; Hui Zhai; Qian Zhao; Xin-Rong Zhou; Fen Liu; Xue-He Zhang; Xiao-Ming Gao; Xiao-Mei Li; Yi-Ning Yang
Journal:  Sci Rep       Date:  2020-04-24       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.